Compare CMC & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CMC | PCVX |
|---|---|---|
| Founded | 1915 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.5B | 7.0B |
| IPO Year | 1994 | 2020 |
| Metric | CMC | PCVX |
|---|---|---|
| Price | $69.12 | $56.51 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 4 |
| Target Price | $73.33 | ★ $88.25 |
| AVG Volume (30 Days) | 1.2M | ★ 1.4M |
| Earning Date | 03-26-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.20% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.41 | N/A |
| Revenue | ★ $7,918,430,000.00 | N/A |
| Revenue This Year | $18.81 | N/A |
| Revenue Next Year | $6.34 | N/A |
| P/E Ratio | $30.77 | ★ N/A |
| Revenue Growth | ★ 25.57 | N/A |
| 52 Week Low | $48.14 | $29.10 |
| 52 Week High | $84.87 | $65.00 |
| Indicator | CMC | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 40.00 | 60.67 |
| Support Level | $67.83 | $52.04 |
| Resistance Level | $72.94 | $56.04 |
| Average True Range (ATR) | 2.70 | 2.37 |
| MACD | -0.84 | 0.94 |
| Stochastic Oscillator | 8.15 | 74.71 |
Commercial Metals Co is a manufacturer and supplier of early-stage construction materials, including steel reinforcing bars, concrete pipes, precast products, and soil stabilization solutions. It also produces merchant bar, steel fence posts, and wire rod, serving domestic and some international markets in Europe and Asia. Its products are used in infrastructure and building projects such as highways, bridges, airports, and commercial and residential buildings.
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.